Search results for "Neoplastic"

showing 10 items of 2901 documents

Sequential boost in neoadjuvant irradiation for T3N0-1 rectal cancer: long-term results from a single-center experience.

2016

Purpose To evaluate the influence of radiation dose on tumor regression grade (TRG) and sphincter preservation rate in a series of cT3N0-1 rectal cancer patients treated with neoadjuvant chemoradiotherapy (CT-RT) with or without a sequential radiation boost. Materials and methods Between May 2002 and September 2013, 116 cases were eligible for retrospective evaluation. Radiotherapy was delivered for a total dose of 45 Gy (no boost arm) or 50.4 Gy (boost arm). TRG was evaluated with the Dworak scale. Results Median follow-up was 62 months (range, 12-138 months). The 5-year overall survival and local control rates were 72% and 93%, respectively. Fifty-five patients (47%) were treated with a s…

MaleCancer ResearchTime FactorsTumor downsizingColorectal cancermedicine.medical_treatmentAnal CanalKaplan-Meier EstimateSingle Center030218 nuclear medicine & medical imaging0302 clinical medicineAdjuvantNeoadjuvant therapyDigestive System Surgical ProceduresTumor Regression GradeIleostomyMedicine (all)Colorectal cancer; Radiation therapy; Tumor downsizing; Adenocarcinoma; Adult; Aged; Anal Canal; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Digestive System Surgical Procedures; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Tract; Humans; Ileostomy; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Radiotherapy Dosage; Radiotherapy Adjuvant; Rectal Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome; Urogenital System; Medicine (all); Oncology; Cancer ResearchRadiotherapy DosageGeneral MedicineChemoradiotherapyMiddle AgedNeoadjuvant TherapyRadiation therapyTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleRadiologyFluorouracilmedicine.drugAdultmedicine.medical_specialtyUrogenital SystemAntineoplastic AgentsAdenocarcinomaCapecitabine03 medical and health sciencesmedicineHumansCapecitabineAgedNeoplasm StagingRetrospective StudiesRadiotherapybusiness.industryRectal Neoplasmsmedicine.diseaseColorectal cancerRadiation therapyGastrointestinal TractConcomitantRadiotherapy AdjuvantbusinessOrgan Sparing TreatmentsChemoradiotherapyFollow-Up StudiesTumori
researchProduct

Reduced expression of Hugl-1, the human homologue of Drosophila tumour suppressor gene lgl, contributes to progression of colorectal cancer.

2005

The human gene, human giant larvae (Hugl-1/Llg1/Lgl1) has significant homology to the Drosophila tumour suppressor gene lethal(2)giant larvae (lgl). The lgl gene codes for a cortical cytoskeleton protein, Lgl, that binds Myosin II and is involved in maintaining cell polarity and epithelial integrity. The human protein, Hugl-1 contains several conserved functional domains found in Lgl, suggesting that these proteins may have closely related functions. Whether loss of Hugl expression plays a role in human tumorigenesis has so far not been extensively investigated. Thus, we evaluated tumour tissues from 94 patients undergoing surgery for colorectal cancer (CRC) for loss of Hugl-1 transcription…

MaleCancer ResearchTranscription Geneticmedicine.disease_causeCell MovementNeoplasmsGene expressionDrosophila ProteinsIntestinal MucosaCytoskeletonReverse Transcriptase Polymerase Chain ReactionCell CycleCell migrationCell DifferentiationMiddle AgedImmunohistochemistryGene Expression Regulation NeoplasticDrosophila melanogasterDisease ProgressionFemaleColorectal NeoplasmsAdenomaAdultTumor suppressor geneBlotting WesternGreen Fluorescent ProteinsDown-RegulationBiologyCell LineDownregulation and upregulationCell Line TumorGeneticsmedicineCell AdhesionAnimalsHumansCell adhesionMolecular BiologyGeneTumor Suppressor ProteinsCarcinomaProteinsProtein Structure TertiaryCytoskeletal ProteinsMicroscopy FluorescenceTumor progressionImmunologyCancer researchCaco-2 CellsCarcinogenesisOncogene
researchProduct

Sustained telomere erosion due to increased stem cell turnover during triple autologous hematopoietic stem cell transplantation.

2007

Telomeres cap chromosomal ends and are shortened throughout a lifetime. Additional telomere erosion has been documented during conventional chemotherapy or hematopoietic stem cell transplantation. Previous studies of stem cell transplantation reported variable amounts of telomere shortening with inconsistent results regarding the persistence of telomere shortening. Here we have prospectively studied telomere length and proliferation kinetics of hematopoietic cells in aggressive non-Hodgkin lymphoma patients who underwent a four-course high-dose chemotherapy protocol combined with triple autologous stem cell transplantation. We observed sustained telomere shortening in hematopoietic cells af…

MaleCancer ResearchTransplantation Conditioningmedicine.medical_treatmentHematopoietic stem cell transplantationAntibodies Monoclonal Murine-DerivedAutologous stem-cell transplantationAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorLymphocytesProspective StudiesCellular SenescenceEtoposideMyelopoiesisLymphoma Non-HodgkinAntibodies MonoclonalHematologyMiddle AgedTelomereCombined Modality TherapyHaematopoiesisVincristineFemaleStem cellRituximabCell DivisionPrednisoloneTransplantation AutologousDrug Administration ScheduleGeneticsmedicineHumansMolecular BiologyCyclophosphamideChemotherapyPeripheral Blood Stem Cell Transplantationbusiness.industryCell BiologyMyeloablative Agonistsmedicine.diseaseHematopoietic Stem CellsTelomereLymphomaTransplantationClinical Trials Phase III as TopicDoxorubicinImmunologyCancer researchbusinessGranulocytesExperimental hematology
researchProduct

Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT‘91

2009

PURPOSE: To analyse long-term outcome and clinical prognostic factors in medulloblastoma. METHODS: We analysed 280 patients with medulloblastoma (3-18 years) included from 1991 to 1997 in the randomised multicentre trial HIT'91 comparing pre-('sandwich') and postradiation ('maintenance') chemotherapy (median follow-up of survivors for 10 years). RESULTS: In 187 patients with complete staging, overall survival (OS) was higher after maintenance compared to sandwich treatment for M0 (10-year OS 91% and 62%, p=0.001) and M1 patients (10-year OS 70% and 34%, p=0.020). In M2/3 disease, 10-year OS was 42% and 45%. Incomplete staging, metastases, younger age and sandwich chemotherapy were independe…

MaleCancer ResearchVincristinePediatricsmedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmentAntineoplastic AgentsDrug Administration Schedulelaw.inventionMaintenance therapyRandomized controlled triallawmedicineHumansCerebellar NeoplasmsChildSurvival rateNeoplasm StagingProportional Hazards ModelsMedulloblastomaChemotherapybusiness.industryProportional hazards modelNeoplasms Second Primarymedicine.diseaseCombined Modality TherapySurvival RateClinical trialTreatment OutcomeOncologyVincristineChild PreschoolFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesMedulloblastomamedicine.drugEuropean Journal of Cancer
researchProduct

Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International society of paediatric oncology (SI…

1995

In a multicentre randomised clinical trial 364 children with biopsy proven medulloblastoma were randomly assigned to receive or not pre-radiotherapy chemotherapy. Children with total or subtotal removal of the tumour, no evidence of invasive brain stem involvement, and no evidence of metastatic disease either within or without the cranium were designated "low risk", those with gross residual tumour, evidence of invasive brain stem involvement or metastases in the central nervous system were designated "high risk". All children were prescribed 55 Gy to the tumour bearing area. "Low risk" children could be randomised to "standard" radiotherapy 35 Gy to the craniospinal axis or "reduced" dose …

MaleCancer ResearchVincristinemedicine.medical_specialtyPediatricsTime FactorsAdolescentmedicine.medical_treatmentProcarbazinelaw.inventionRandomized controlled trialRecurrenceRisk FactorslawAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineProspective StudiesCerebellar NeoplasmsChildProspective cohort studyMedulloblastomabusiness.industryInfantRadiotherapy Dosagemedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryRadiation therapyClinical trialOncologyChild PreschoolPediatrics Perinatology and Child HealthFemalebusinessCraniospinalMedulloblastomamedicine.drugMedical and Pediatric Oncology
researchProduct

Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform

2019

Background/Aim: The Philadelphia chromosome is the most frequent cytogenetic abnormality in chronic myelogenous (CML). More than 95% of CML patients are diagnosed with the e13a2 or e14a2 BCR-ABL1 fusion transcripts while, in about 1% of these individuals, the break generates the e1a2 rearrangement. Furthermore, about 5% of CML patients are diagnosed with rare BCR-ABL1 fusion transcripts, such as e19a2, e8a2, e13a3, e14a3, e1a3 and e6a2. However, there is limited evidence concerning the clinical and prognostic implications of these infrequent oncogenic variants for CML patients receiving tyrosine kinase inhibitors (TKIs). Case Report: We describe a novel atypical e12a2 insertion/deletion (In…

MaleCancer Researchbcr-ablFusion Proteins bcr-ablBCR-ABL1; CML; E12a2; E13a2; Nilotinib; Ponatinib; TKIs; Antineoplastic Combined Chemotherapy Protocols; Fusion Proteins bcr-abl; Humans; INDEL Mutation; Imidazoles; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Protein Isoforms; Pyridazines; Pyrimidines; Treatment Outcomechemistry.chemical_compoundExon0302 clinical medicineINDEL Mutationhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsProtein IsoformsChronicCMLLeukemiaPonatinibImidazolesGeneral MedicineMiddle AgedTKIPyridazinesTreatment OutcomeOncology030220 oncology & carcinogenesisPonatinibPyridazineTyrosine kinaseINDEL MutationE13a2Humanmedicine.drugPhiladelphia chromosome03 medical and health sciencesMyelogenousLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansImidazoleAntineoplastic Combined Chemotherapy Protocolbusiness.industryBreakpointProtein IsoformFusion Proteinsmedicine.diseaseNilotinibBCR-ABL1PyrimidinesPyrimidinechemistryNilotinibTKIsCancer researchBCR-ABL PositivebusinessE12a2Myelogenous
researchProduct

Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA a…

2019

Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. A CK (CK) was defined as the presence of ≥2 ACA, and a very CK (CK+) as ≥3 ACA. Eighty-nine patients (8%) had a CK, of whom 41 (4%) had CK+. The 5-year cumulative incidence of relapse (CIR) in patients with CK was 18%, and 12% in those with <2 ACA (p=.09). Among patients wi…

MaleCancer Researchcomplex karyotypeANTHRACYCLINE MONOCHEMOTHERAPYmedicine.medical_treatmentAbnormal KaryotypechemotherapyGastroenterologyLeukocyte Count0302 clinical medicineLeukemia Promyelocytic AcuteRecurrenceAcute promyelocytic leukemiaAntineoplastic Combined Chemotherapy ProtocolsPROGNOSTIC-SIGNIFICANCECumulative incidenceATRAChildIn Situ Hybridization FluorescenceAged 80 and overrelapsePETHEMAIncidence (epidemiology)ADDITIONAL CHROMOSOME-ABNORMALITIESAge FactorsHematologyMiddle AgedPrognosisARSENIC TRIOXIDEFLT3 MUTATIONSLeukemiaTreatment OutcomeOncologyChild Preschool030220 oncology & carcinogenesisCytogenetic AnalysisFemaleAdultAcute promyelocytic leukemiamedicine.medical_specialtyCYTOGENETIC CHANGESAdolescentYoung Adult03 medical and health sciencesInternal medicineStatistical significanceComplex KaryotypemedicineHumansClinical significanceAgedCONSOLIDATION THERAPYChromosome AberrationsChemotherapybusiness.industrymedicine.diseaseRISK-ADAPTED TREATMENTTRANS-RETINOIC ACIDATRA Acute promyelocytic leukemia chemotherapy complex karyotype prognostic relapsebusinessprognostic030215 immunologyLeukemia & Lymphoma
researchProduct

Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to eto…

1999

BACKGROUND The mechanisms of drug resistance associated with advanced, hormone-independent prostate carcinoma are poorly understood. The human prostate carcinoma PC-3 cell line, derived from a metastatic tumor and lacking androgen receptors, represents a useful model to investigate drug resistance. METHODS The effects of oncostatin M (OM), antiinterleukin-6 (IL-6) treatment, or interference with the gp130-mediated signaling on etoposide- or cisplatin-mediated cytotoxicity were investigated. RESULTS Both endogenous and exogenous IL-6 and exogenous OM up-regulated cell growth and enhanced resistance of PC-3 tumor cells to both etoposide and cisplatin. The influence of IL-6 is controlled by tr…

MaleCancer Researchmedicine.drug_classAntineoplastic AgentsOncostatin MBiologyCell surface receptorAntigens CDCyclohexenesmedicineCytokine Receptor gp130Tumor Cells CulturedHumansReceptorEtoposideEtoposideMembrane GlycoproteinsCell growthInterleukin-6TerpenesOncostatin MProstatic NeoplasmsGlycoprotein 130Receptor antagonistAntineoplastic Agents PhytogenicGenisteinOncologyDrug Resistance NeoplasmCancer researchbiology.proteinMonoterpenesSignal transductionCisplatinPeptidesmedicine.drugSignal Transduction
researchProduct

Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hemat…

2004

BACKGROUND Continuous oral treatment with topotecan may be more effective than the typical 1-day and 5-day treatment schedules. In previous studies of continuous treatment with topotecan, increased intestinal side effects were reported in adult patients; however, the experience in pediatric patients and patients with high-grade glioma is quite limited. METHODS Thirty-two pediatric patients with recurrent high-grade glioma (16 females and 16 males; median age, 9.5 years) were enrolled in the current Phase I/II study. Tumor locations included the cerebral cortex (n = 5), pons (n = 18), and other sites (n = 9). An injectable formulation of topotecan was administered orally, in ice-cold orange …

MaleCancer Researchmedicine.medical_specialtyAdolescentAdministration OralAntineoplastic AgentsGastroenterologyDrug Administration Schedule03 medical and health sciences0302 clinical medicinePharmacokineticsOral administrationInternal medicineGliomaMedicineHumansDosingChild030304 developmental biologyOrange juice0303 health sciencesbusiness.industryBrain NeoplasmsGliomamedicine.disease3. Good healthSurgeryTreatment OutcomeOncology030220 oncology & carcinogenesisChild PreschoolToxicityTopotecanFemalebusinessTopotecanProgressive diseasemedicine.drugCancer
researchProduct

Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival.

2010

Abstract Aims The role of IGF system in the pathogenesis of Ewing’s sarcoma (EWS) is well-documented. However, still little information is available about the value of IGF system components as indicators of prognosis. Understanding the clinical role for IGF system in EWS patients may be important because different subtypes of patients have distinct outcome and may require different treatment protocol. We evaluated the expression of insulin-like growth factor (IGF)-receptor (IGF-IR), insulin receptor (IR), IGF-I and some major intracellular mediators (IRS1, p-ERK) in specimens from EWS patients with primary localised untreated tumours. Patients and methods 290 samples were used for immunohis…

MaleCancer Researchmedicine.medical_specialtyAdolescentmedicine.medical_treatmentEnzyme-Linked Immunosorbent AssaySarcoma EwingPathogenesisInsulin-like growth factorInternal medicinemedicineHumansInsulin-Like Growth Factor IReceptorChildbiologyReverse Transcriptase Polymerase Chain ReactionEwing's sarcomaCancermedicine.diseasePrognosisImmunohistochemistryIRS1Gene Expression Regulation NeoplasticInsulin receptorEndocrinologyTreatment OutcomeOncologybiology.proteinCancer researchDisease ProgressionFemaleSarcomaEuropean journal of cancer (Oxford, England : 1990)
researchProduct